Article Information
History
- May 5, 2020.
Article Versions
- You are currently viewing Version 1 of this article (May 5, 2020 - 10:17).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Perrine Vuagnat1,2,
- Maxime Frelaut3,
- Toulsie Ramtohul4,
- Clémence Basse2,
- Sarah Diakite2,
- Aurélien Noret2,
- Audrey Bellesoeur2,
- Vincent Servois4,
- Delphine Hequet5,
- Enora Laas5,
- Youlia Kirova6,
- Luc Cabel2,
- Jean-Yves Pierga2,7,
- Institut Curie Breast Cancer and COVID Group,
- Laurence Bozec2,*,
- Xavier Paoletti1,8,*,
- Paul Cottu2,* and
- François-Clément Bidard1,2,*,†
- 1UVSQ, Université Paris-Saclay, Saint Cloud, France
- 2Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France
- 3Department of Drug Development and Innovation, Institut Curie, Paris, France
- 4Department of Radiology, Institut Curie, Paris, France
- 5Department of Surgical Oncology, Institut Curie, Paris, France
- 6Department of Radiation Oncology, Institut Curie, Paris, France
- 7Université de Paris, Paris, France
- 8INSERM U900 STAMPM team, Saint Cloud, France
- ↵†Correspondence:
fcbidard{at}curie.fr
↵* equal contribution
Posted May 05, 2020.
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
